Cytokinetics Executive Executes Stock Option Exercise and Subsequent Sale
Andrew Callos, the Executive Vice President and Chief Commercial Officer at Cytokinetics Inc (NASDAQ: CYTK), completed a series of transactions involving company stock on May 1, 2026. The activity included the exercise of non-qualified stock options followed by a sale of common shares totaling $1,030,705. This transaction occurred while the company…